As the speaker of the CFA Society Shanghai webinar—"High-Risk, High-Reward? How to assess the value of a Biotech company?”

Our Managing Director, Mr. Vincent Pang was pleased to be invited by the CFA Society Shanghai to speak on the “High-Risk, High-Reward? How to assess the value of a Biotech company?” webinar.

 

The webinar gathered fellow CFAs that would like to better understand the valuation of biotechnology company. Investors have already been placing more and more attention on the Biotech sector in recent years. However, Unlike the traditional company, the Biotech company have a high failure rate on the products they attempt to invent or the products are unable to obtain regulatory approval. Therefore, investing in biotech industry is considered as a high-risk investment.

 

Vincent introduced the attributes of biotechnology industry and shared the valuation methods for biotechnology company with case studies.

Meet Our People

VINCENT PANG

VINCENT PANG

Managing Director

AVISTA GROUP

vincent.pang@avaval.com

HAILEY JIN

HAILEY JIN

Director

VALUATION ADVISORY

hailey.jin@avaval.com

IVAN LUI

IVAN LUI

Director

VALUATION ADVISORY

ivan.lui@avaval.com

Date: 24 Aug 2021 | Tags: Business Valuation

Privacy & Disclaimer

© COPYRIGHT 2020 AVISTA GROUP, ALL RIGHTS RESERVED

沪ICP备17054339号